Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


R contains benzene ring

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514579000 - Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI

514613000 - Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514622000 C-O- group in R 70
514619000 Nitrogen in R 51
514618000 Sulfur in R 37
514621000 C=O in R 4
20110054034METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS - A method of treating a disease or condition in a warm blooded mammal which disease or condition is suspected to be associated with a microbial infection, comprising: administering an antimicrobial effective amount of a carboxylic acid amide, its isomers or salts thereof, to a subject who is suspected to be infected with a microbe. In one embodiment, the carboxylic acid amide is trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxyphenyl)amide.03-03-2011
20080300314Cooling Compounds - Compounds of the formula I give a cooling sensation to the mouth and skin:12-04-2008
20120322881PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more guanidine fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of dodine, iminoctadine trialbesilate, iminoctadine triacetate, and guazatine12-20-2012
20110306671AMIDE DERIVATIVES OF ETHACRYNIC ACID - The invention provides ethacrynic acid derivatives useful to prevent, inhibit or treat a variety of disorders or diseases including cancer and inflammatory disorders.12-15-2011
Entries
DocumentTitleDate
20080319082Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives - Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.12-25-2008
20100076084Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I)03-25-2010
20100041762SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I) or (II):02-18-2010
20090156682N-(1-Methyl-2Phenylethyl)Benzamide Derivatives - A compound of general formula (I):06-18-2009
20090076155MODULATORS (INHIBITORS/ACTIVATORS) OF HISTONE ACETYLTRANSFERASES - The invention provides the use of certain benzoic acid and benzamide compounds as modulators of enzymes histone acetyltransferases, which are involved in gene expression and cancer and also use of such compounds in the treatment of diseases due to defects in gene regulation predominantly cancer.03-19-2009
20100056636N-Substituted-P-Menthane-3-Carboxamide and Uses Thereof - The present invention relates to substances and compositions having a physiological cooling effect on the skin and the mucosa of the body, especially of the oral cavity, throat and nose. More in particular, the present invention relates to N-substituted-p-menthane-3-carboxamides represented by the following formula (I):03-04-2010
20090012176PROCESS FOR MANUFACTURING ENTACAPONE - Processes for manufacturing entacapone are provided.01-08-2009
20090082460Polyamide-Polyether Block Copolymer - Copolymers having linked internal polyether blocks and internal polyamide blocks have advantageous physical properties and solvent-gelling abilities. The copolymer may be prepared from a reaction mixture that contains 1,4-cyclohexane dicarboxylic acid (CHDA) and poly(alkyleneoxy)diamine (PAODA). Optionally, the reaction mixture contains no monofunctional compound reactive with either amine or carboxylic acid groups, however some of this monofunctional compound may be present. Dimer diamine and/or dimer acid may be present in the reaction mixture. A copolymer may also be prepared from a reaction mixture containing dimer acid and at least two diamine compound(s) including PAODA and short-chain aliphatic diamine having 2-6 carbons (SDA), wherein: a) the reaction mixture comprises x grams of PAODA and y grams of SDA, and x/(x+y) is 0.8-0.98; b) the reaction mixture weighs z grams, and x/z is at least 0.25; and c) the reaction mixture contains either no co-diacid, or comprises a small amount of co-diacid, wherein, if the reaction mixture comprises a small amount of co-diacid, then acid equivalents from co-diacid contribute less than 25% of the total acid equivalents present in the reaction mixture.03-26-2009
20100063155N-(3-PHENYLPROPYL)BENZAMIDE DERIVATIVES - A compound of general formula (I):03-11-2010
20080280989Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same - Disclosed is a hydroxybenzamide derivative represented by the following Formula. A method for preparing the same and a cosmetic composition comprising the same are also disclosed. More particularly, the hydroxybenzamide derivative is obtained by reacting a hydroxybenzoic acid having a protecting group introduced thereto with a hydroxyphenyl amine to form a benzamide derivative and by hydrolyzing the benzamide derivative in an aqueous base solution to form a hydroxybenzamide derivative. The cosmetic composition comprising the hydroxybenzamide derivative as an active ingredient has excellent anti-oxidative, anti-aging and skin wrinkle-alleviating effects. wherein R1 represents a C1˜C10 alkyl group, and n is an integer ranging from 1 to 3.11-13-2008
20080287547Glycine Transport Inhibitors - The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.11-20-2008
20090143473USE OF INHIBITORS OF THE CELLULAR NA+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS - Use of inhibitors of the cellular Na06-04-2009
20090062396Novel Haloalkoxy-Substituted Salicylic Anilides - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.03-05-2009
20090076157DEUTERIUM-ENRICHED SENICAPOC - The present application describes deuterium-enriched senicapoc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20110237678N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES - A compound of general formula (I). A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.09-29-2011
20090111879INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION - The present invention relates to a phenylalanine derivative of Formula (I) wherein X04-30-2009
20090082459DEUTERIUM-ENRICHED GUANFACINE - The present application describes deuterium-enriched guanfacine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20090036538TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS - The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.02-05-2009
20110124735CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS - The present invention relates to the use of a particular group of carbonylamino derivatives for the treatment or alleviation of a disease or condition relating to certain inflammatory disorders.05-26-2011
20120202885METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES - Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.08-09-2012
20110039936N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for Use in the Treatment of Pain and Inflammation - Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5′ are independently —H, —OH or —OR02-17-2011
20100056637TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS - The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease.03-04-2010
20100029776PESTICIDAL COMPOSITION COMPRISING FENAMIDONE AND AN INSECTICIDE COMPOUND - A composition comprising fenamidone (a) and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1000 to 1000/1.02-04-2010
201000297774-[(E)-2-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPTHALENYL)-1-PROPENYL- ]BENZOIC ACID ANALOGS AND METHOD OF MANUFACTURE AND USE THEREOF - Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment.02-04-2010
20090076156USE OF A NORADRENERGIC AGONIST, E.G. GUANFACINE, FOR THE TREATMENT OF COGNITIVE DISORDERS - The present invention relates to the use of a noradrenergic agonist for the treatment of a patient with a cognitive disorder resulting from acquired brain damage, wherein the cognitive disorder includes, for example, hemi-spatial neglect.03-19-2009
20120041068Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility - An extended release preparation of an active pharmaceutical ingredient with pH dependent solubility dissolved or dispersed in a semi-solid or liquid nonionic solubilizer and further containing a non-pH dependent sustained release agent as well as a process for the preparation thereof are provided.02-16-2012
20080227863Organic Compounds - The invention relates to compounds of the general formula09-18-2008
20110313046COMBINATION THERAPY WITH LISDEXAMPHETAMINE AND EXTENDED RELEASE GUANFACINE - The present invention relates to treating children and adults with suboptimal responses to Attention Deficit Hyperactivity Disorder (ADHD) monotherapy. More specifically, the present invention relates to a method for treating ADHD in a patient which comprises administering to the patient an extended release guanfacine composition adjunctively with a lisdexamphetamine composition.12-22-2011

Patent applications in class R contains benzene ring

Patent applications in all subclasses R contains benzene ring